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Water soluble platinum complexes are a recent area of emphasis of cisplatin chemistry. 
The water soluble complexes could have a reduced toxicity compared with cisplatin. 
Oxaliplatin, which has an oxalate leaving group, has previously been shown to have less 
nephro-toxicity and higher water solubility than cisplatin. [Pt(en)(oxalate)] (en = 
ethylenediamine) has been prepared from Pt(en)Cl2 and silver oxalate. This complex has 
been reacted with methionine and N-acetylmethionine at different molar ratios. At high 
Pt: methionine ratios, chelates with the sulfur and nitrogen atoms of the methionine are 
dominant; at lower Pt: methionine ratios, a bis-methionine product is formed.  The en 
ligand is displaced by methionine but not N-acetylmethionine. 
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I.  INTRODUCTION 
 
1. History: 
Cisplatin, [cis-diamminedichloroplatinum(II)] (CAS 15663-27-1), is widely used 
in the chemotherapy of solid tumors, testicular cancer, ovarian cancer, and lung cancer as 
well as neck tumors and head cancer
1
. Many more oral derivatives of cisplatin are being 
synthesized every year. There are over 3000 cisplatin analogs that have been tested, with 
28 that are currently awaiting clinical trials. Typically, it is estimated that more than 
10,000 compounds need to be screened in order to obtain a new, effective anticancer 
drug
1
. 
Cisplatin was first described by M. Peyrone in 1839
1
 and is historically called 
Peyrone's salt. Transplatin and cisplatin are isomeric compounds, and the molecular 
structure differences between the two complexes were resolved by Werner in 1845
2
. In 
the 1960s, Barnett Rosenberg and Van Camp found that use of a platinum electrode 
inhibited binary fision in E. coli bacteria when an electric field was created. While the 
bacteria grew to 300 times their normal length, cell division would fail
3
.  
Rosenberg conducted a series of experiments to test the effects of platinum 
compounds and coordination complexes on sarcomas. The key research was done at 
Michigan State University; specifically, cisplatin and other platinum complexes were 
tested on tumors artificially implanted in rats
3
. 
Many studies have used mouse leukemia L1210/0 cells to react with cisplatin, 
which increases DNA excision repair capacity and causes DNA defect mutagen 
hypersensitivity
4
. Cisplatin was tested and established as a potential drug with curative 
3 
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ability in the treatment of testicular cancer. The Food and Drug Administration (FDA) 
approved cisplatin for metastatic ovarian tumors for a Phase I clinical trial in 1971. 
Commercially, cisplatin was named Platinol
5
.  
2. Types of platinum compounds:  
Platinum has two dominant charge states, +2 and +4
6
. The +2 charge state forms 
square planar complexes and the +4 forms octahedral complexes. The earliest synthesized 
anti-tumor drugs were cis-[Pt
II
(NH3)2Cl2] and cis-[Pt
IV
(NH3)2Cl4]. Most of the well-
known platinum anticancer complexes have a +2 charge. The general formula of the 
anticancer complexes is cis-[Pt
II
X2(NHR2)2], in which R = organic fragment and X = 
leaving group such as chloride, chelating bis-carboxalate or oxalate.  
 
Figure 1. cis-dichlorodiammineplatinum(II) and cis-tetrachlorodiammineplatinum(IV)
7
. 
Cisplatin has a 90% curative rate for ovarian and testicular cancers. Although 
transplatin and cisplatin are geometric isomers, trans-species suppress growth at higher 
concentration and are inactive at low concentrations (ppm). Trans-
5 
 
 
 
diamminedichloroplatinum(II), (trans-DDP, or transplatin), is therefore clinically 
ineffective 
7
. 
In Figure 2, the structures of cisplatin and other platinum anti cancer drugs are 
shown: (1) Cisplatin; (2) Carboplatin; (3) Nedaplatin; (4) Oxaliplatin; (5) JM-216; bis-
acetato-ammine-dichlorocyclohexylamine platinum(IV); (6) AMD473; cis-
Amminedichloro (2-methylpyridine) platinum(II); (7)  Dinuclear complex;  and (8) 
Trinuclear complex.
 
 
Figure 2. Cispaltin Family: (1) Cisplatin; (2) Carboplatin; (3) Nedaplatin; (4) Oxaliplatin; 
(5) JM-216; bis-acetato-ammine-dichlorocyclohexylamine platinum(IV); (6) AMD473; 
cis-Amminedichloro (2-methylpyridine) platinum(II); (7)  Dinuclear complex;  and (8) 
Trinuclear complex. 
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Carboplatin (cyclobutane-1,1-dicarboxylic acid), also called Azanide, ( 41575- 
94- 4) is one of many third generation platinum compounds that have been approved for 
clinical usage in the United States. Carboplatin was discovered and developed at the 
Insitute of Cancer Research in London. In 1989, Carboplatin, still under the brand name 
Paraplatin, was approved by the FDA (Food and Drug Administration). Starting in 
October 2004, generic versions of the drug became available. Carboplatin is a 
chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, 
head and neck cancers)
 9
. Carboplatin has less nephrotoxicity, neurotoxicity, ototoxicity 
and emetogenesis and is more stable than cisplatin. The platinum-based antineoplastics 
have a broad spectrum of antitumor activity in the treatments of carcinomas of ovarian, 
testicular, bladder, small and non–small cell lung, head and neck carcinoma, and 
seminoma. 
Oxaliplatin, {(R, R)-1,2-diaminocyclohexane(ethanedioate-O,O)platinum(II)} 
(63121-00-6)   has an oxalate ligand as a leaving group. It is typically administered with 
fluorouracil and leucovorin in a combination used in the treatment of colorectal cancer. 
Oxaliplatin is a platinum-based cancer chemotherapy drug, classified as an alkylating 
agent. The alkylating agents are not capable of actually adding alkyl groups to DNA, but 
simply work by a similar mechanism
10
. It was discovered in 1976 at Nagoya City 
University by Professor Yoshinori Kidani, and was subsequently in-licensed by 
Debiopharm. Oxaliplatin was developed as an advanced colorectal cancer treatment
11. It 
is known that a diaminocyclohexane group contributes greater cytotoxicity than cisplatin 
and carboplatin. Oxaliplatin is not generally cross-resistant to cisplatin or carboplatin. All 
are capable of forming platinum complexes producing inter- and intrastrand DNA cross 
7 
 
 
 
links with neighboring guanine residues, resulting in DNA-mismatch repair (MMR) 
activity in the cancer cells. 
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II. PROPERTIES OF CISPLATIN 
1. Physical properties12: 
 Table 1: Physical properties of cis-diamminedichloroplatinum(II)
 
 
Formal Name  
cis-diamminedichloroplatinum(II) 
CDDP   
 
 
         (CAS 15663-27-1) 
Common/ 
Commercial Names  
Cisplatin/Platinol  
Agent  Anti-neoplastic  
Molecular Formula  Cl2H6N2Pt  
Molecular Weight  300.1  
Normal State  Crystalline solid  
Color  Deep yellow (crystalline solid) & Clear (reconstituted solution)  
Structure  Tetragonal (square) planar  
Symmetry  C2V  
Melting Point  Decomposes at 270°C to give chlorine gas and nitrogen oxides  
Solubility Soluble in water and saline  
Insolubility Ethanol, Hexane, Benzene and Acetone 
 
8 
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2. Chemical properties: 
a) Aqueous solubility: 
Cisplatin is water soluble. The chloride ligands undergo slow displacement 
with a water (an aqua ligand) molecule. The aqua ligand in the resulting 
[PtCl(H2O)(NH3)2]
 +
 is easily displaced, allowing cisplatin to coordinate to a basic 
site of DNA. Subsequently, the platinum cross-links a second base via 
displacement of the other chloride ligands
13
. 
cis - [ Pt(NH3)2Cl2 ] + H2O Cl
-   +  cis- [Pt(NH3)2Cl(H2O)]
+ 
cis - [ Pt(NH3)2Cl(H2O) ]
+ + H2O  Cl
- + cis- [Pt(NH3)2(H2O)2]
2+ 
 
   Figure 3. Mechanism for aquation of cisplatin
14
. 
 
 
Figure 4. Aquation and deprotonation of cisplatin
15
. 
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b) Chemical activity: 
 Stability  
Lyophilized Cisplatin powder should be stored under refrigeration (2-8 °C) 
and kept from light. Cisplatin solution (Platinol-Bristol) should be stored above 
freezing and below 25°C, and protected from light. The half life of a di-aqua 
complex is about 5 hours at 30°C at pH 7. The chloride ligands of cisplatin may 
also be substituted by a variety of other nucleophiles like –OH. 
 Stability in solution 
 Cisplatin is hydrolyzed in water, losing a chloride ion and gaining a water 
molecule to form the monohydrated complex (MHC). MHC in its protonated form, 
monoaqua cisplatin, is positively charged and highly reactive with a pKa of 6.56 
which is quite close to physiological pH
16
. At physiological pH (7.4) 85% of the 
MHC will be in its deprotonated form, the much less reactive monohydroxo 
cisplatin. The important cisplatin equilibria are affected by both pH and chloride 
concentrations of administration solution and body fluid. 
 
 
 
 
 
 
11 
 
 
 
III. SYNTHESIS AND BIOLOGICAL ACTIVITY 
1. Synthetic procedures: 
Cisplatin can be synthesized by many procedures, including:  
 Addition of ammonia to ammonium tetrachloroplatinum(II)  
 Heating of tetraammineplatinum(II) chloride at 250 °C  
 Reaction of ammonium carbonate with tetrachloroplatinic(II) acid  
The following preparation is a modification of Ramberg and Peyrone respectively, and 
involves a minimum number of side reactions which serves which serves to maximize 
yield.  
a) Synthesis equation17: 
2K2[PtCl6]  +  N2H4  2HCl   2K2[PtCl4]  +  N2+  6 HCl 
K2 [PtCl4]  +   2 NH3      cis- [ Pt (NH3)2 Cl2] +  2KCl 
 
b) Overall reaction scheme: 
 
Figure 5. Synthetic scheme for the synthesis of cisplatin
18
. 
11 
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2. Biological activity of cisplatin  
a)  Cisplatin reaction with DNA 
 
Figure 6. Cisplatin reacts with DNA and Proteins
19
. 
The platinum in cisplatin cross-links a second base via displacement of the second 
chloride ligand
18
. Cisplatin cross-links DNA in several different ways, interfering with 
cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in 
turn activate apoptosis when repair proves impossible. 
The most notable reaction of cisplatin reacting with DNA is the formation of 1, 2-
intrastrand cross-links on the purine bases adenine (A) and guanine (G). A dominating 
preference for initial attacks at N7-position of guanine has been established 
experimentally. Cisplatin binding to purines is preferred with guanine favored over 
adenine
20
. Following the thermodynamics and kinetics for the binding of the antitumor 
drug cisplatin, the monofunctional platination of guanine requires less energy than that of 
adenine. Cisplatin-G has a stronger molecular orbital interaction than the hydrogen bond 
13 
 
 
 
between the chloride ligand of cisplatin and the H2N-C6 group of adenine. These cross-
links include 1,2-intrastrand d(GpG) adducts, 1,2-intrastrand d(ApG), and 1,3-intrastrand 
d(GpXpG). Almost 90% of adducts are the 1,2- d(GpG) adducts. Much less common is 
the 1,2-intrastrand d(ApG) adducts. 1,3-intrastrand d(GpXpG) adducts occur but are 
readily excised by the nucleotide excision repair (NER) mechanism.  
Furthermore, cisplatin also interacts with cellular proteins, particularly HMG 
(High Mobility Group) domain proteins, which can bind specifically to cisplatin- 
modified DNA and be a more advanced mechanism of interfering with mitosis, although 
this is probably not its primary method of action
21
. 
 
Figure 7. Mechanism of formation of cisplatin-DNA adducts. 
(k1, k2, k3 are equation-rate constants, k1=1.9 ×10
-4 
s
-1
, k2= 2.3 ×10
-4
 s
-1
, kp1 and kp2 
are platination-rate constants, kc is the chelation-rate constant
22
).
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b) Cisplatin reaction with protein 
Cisplatin not only reacts with DNA, but also binds to a number of extra- and 
intracellular proteins. The reaction with amino acids is most common with the sulfur 
donors, Cys and Met, also with the nitrogen donor to His
23
. The high affinity of platinum 
compounds for sulfur atoms could lead to platination for proteins
24
. Those proteins could 
serve as a drug reservoir for the nucleus of the cell. There are many studies that report the 
intermediate platinum binding on O- and N- donor atoms
25
. The intra-molecular 
competition of cisplatin with SAH (S-adenosyl-L-homocysteine), and SGH (S-guanosyl-
L-homocysteine), between a sulfur-containing amino acid moiety and the nitrogen atom 
of a nucleobase, however, shows no coordination, either to the adenine N1 or to the N7 
atom. From this competition reaction, the Pt-sulfur interaction is kinetically preferred, 
while the Pt with guanine-N7 is often thermodynamically favored
20, 26
. 
c)  Cisplatin side effects 
The substantial body of literature documents the side effects of platinum 
compounds. The side effects associated with cisplatin (at single doses ≥ 50 mg/m3) 
includes nausea, vomiting, nephrotoxicity, neuropathy, ototoxicity and myelosuppression. 
The nephrotoxicity of the parent compound, cisplatin, almost led to its abandonment, but 
more novel platinum drugs developed for reduced side effects. The development for 
novel platinum anticancer drug is a driving force behind both the search for less toxic 
analogues and for more effective treatments. The hydrated cisplatin compounds were 
found to reduce side effects and prevent acute renal failure
27
. The novel platinum 
15 
 
 
 
compound analogues, carboplatin and oxaliplatin, which are less toxic than cisplatin, are 
better hydrated and more easily replaced on the chelate.  
[Pt(en)(H2O)2]
2+
, a carboplatin analogue, can react with methionine-containing di- 
and tri-peptides (met-Hgly, met-gly-Hgly) in the pH range of 2.5-11.0. Different pH leads 
to different chelation with N(amino), S(thioether) or N(amino), and N’(amide)28. 
d)  Cisplatin, Carboplatin and Oxaliplatin 
Advances in pharmaceutical research are crucial for improving the design of 
compounds to reduce toxic side effects by increasing the water solubility of anti-cancer 
drugs. Carboplatin is an analogous of cisplatin that is more easily administered and 
reduced the side effect at standard doses. Carboplatin has a bidentate dicarboxylate ligand 
as its leaving group instead of the more labile chloride ligands. It has good water 
solubility, exhibits excellent activity against a variety of leukemias and solid tumors with 
low nephrotoxicity and pharmacokinetic stability
29
. The other toxicities of carboplatin are 
generally milder and better tolerated than those of cisplatin. This is due to a different 
pharmacokinetic profile resulting from the substitution of a more stable leaving group. 
Oxaliplatin
30
 has less nephrotoxicity than cisplatin, presumably related to it is 
more slowly hydrolyzed leaving group. The leaving group, oxalate, is the divalent anion 
C2O4
2−
 or (COO)2
2−
. It is an excellent ligand for metal ions, and usually binds as a 
bidentate ligand forming a 5-membered MO2C2 ring. The drug, oxaliplatin, exhibits 
improved water solubility relative to cisplatin, and avoids the dose-limiting side-effect of 
nephrotoxicity. 
16 
 
 
 
Our current study focuses on [Pt(en)ox]
31
, oxalate platinum ethylenediamine, 
where en is ethylenediamine and ox is oxalate. The compound features a square planar 
coordination complex and is classified as an alkylating agent and a coordination complex.          
Oxalate, is a good leaving ligand and similar to oxaliplatin, which is water soluble, 
and easily be replaced. The features for the bidentate ligand, ethylenediamine, would be 
less steric bulk and symmetry with two monodentate ammine ligand.  
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IV. MATERIALS AND METHODS 
1. Materials 
Table 2. Oxalic acid (anhydrous) 
Company name: ARCOS ORGANICS  
C.A.S No: C.A.S 144-62-7 
Molecular formula C2H2O4 
Molecular weight  MW= 90.04 g/mol 
    
    Table 3. Silver nitrate, 99+% 
Company name: Sigma –Aldrich  A.C.S reagent 
C.A.S No: C.A.S 7761-88-8 
Molecular formula AgNO3 
Molecular weight  MW= 169.88 g/mol 
 
  Table 4. Silver oxalate 
Chemical Name: Silver oxalate 
Chemical form Ag2C2O4   
 Molecular weight MW= 303.75 g/mol 
 
Table 5. Dichloro(ethylenediamine) platinum(II) 99% 
Company name:  Sigma –Aldrich   
C.A.S No: C.A.S  14096-51-6 
Molecular formula C2H8Cl2N2Pt  
Molecular weight  MW= 326.1 g/mol 
 
Table 6. Methionine (Met) 
Company name: ACROS Organics 
C.A.S No: C.A.S  63-68-3 
Molecular formula C5H11NO2S   
Molecular weight  MW= 149.21 g/mol 
Table 7. N-Acetyl-L- Methionine (N-AcMet) 
Company name: ACROS Organics 
C.A.S No: C.A.S 65-82-7 
Molecular formula C7H13NO3S   
Molecular weight  MW= 191.25 g/mol 
 
17 
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Table 8. Deuterium oxide, 99.9% 
Company name: Sigma –Aldrich   
C.A.S No: C.A.S 7789-20-0 
Molecular formula D2O  
Molecular weight  MW= 20.03 g/mol 
 
2. Methods 
1) Synthesis of Silver Oxalate  
A sample of 450 mg of oxalic acid and 1690 mg of silver nitrate was prepared and 
to an amber vial. A 20 mL sample of deionized water were added and the mixture was 
stirred for at least one hour. The insoluble silver oxalate was collected by vacuum 
filtration. The yield is approximately 95%. 
2) Synthesis of Pt(en)ox 
Dichloride platinum(II)-ethylenediamine [Pt(en)Cl2],was reacted with silver 
oxalate in an amber vial for at least 18 hours at room temperature. As the reaction 
processed, the chloride ion of the platinum compound was replaced by the oxalate, and 
AgCl formed as a white precipitate. The solution was filtered through celite powder, and 
the solution was placed on the rotary evaporator to dry. The resulting solid is [Pt(en)ox]. 
3) Nuclear Magnetic Resonance, NMR32 
NMR spectra were collected on a JEOL Nuclear Magnetic Resonance Spectrometer 
Eclipse 500 MHz in D2O. The chemical shift reference was set to HOD at 4.76 ppm.  
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3. Reactions: 
1) Reactions of Pt(en)ox and Methioine: 
The reaction between the water soluble platinum compound, [Pt(en)ox] 
(339.09g/mol), and Methionine (149.21 g/mol) was monitored at mole ratios of  2:1, 4: 1 
and 1:1, and 1:2. Additionally 1.5 mL of D2O was added to the amber vial. The solution 
was transferred to an NMR tube, after keeping the pH around 4.0-5.0. The solution was 
checked with NMR spectroscopy between 4 hours and 24 hours. 
2) Reaction of Pt(en)ox and N-acetylmethioinine: 
The reaction between [Pt(en)ox]  and N-acetylmethionine was followed at a mole 
ratios of 2:1, 1:1 and 1:2, at the pH value. The NMR spectrum was checked between 4 
hours and 24 hours. 
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V. RESULTS 
1. Reaction of [Pt(en)ox] with N-Acetylmethionine (N-AcMet): 
a) [Pt(en)ox] reacted with N-Acetylmethionine (N-AcMet) at a 2:1 molar ratios 
The reaction was monitored by 
1
H NMR spectroscopy at 4 and 24 hours (Figure 8 
and 9). The signal after 2.5 ppm is assigned to the en ligand of the unreacted platinum 
compound. Signals around 2.5 ppm are due to the S-CH3 resonance at the products. The 
original S-CH3 signal of unreacted N-AcMet is around 2.0 ppm, but the signal shifts to 
2.4 ppm due to the reaction with the platinum compound. The predicted product would 
only have one N-AcMet coordinated via sulfur and nitrogen atoms.  
 
Figure 8. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 2: 1, in D2O 4 hours. 
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Comparing Figure 8 and Figure 9, the peak at 2.5ppm is slightly different between 
4 and 24 hours, the signal on 2.5 ppm on the 24 hours is getting stronger
33
. The reaction 
at the same molar ratio would be more activity by following the time. 
 
Figure 9. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 2: 1, in D2O 24 hours. 
 
22 
 
 
 
The predicted compound for mono adduction, the [Pt(en)(N-AcMet-S, N)] is: 
 
Figure 10. Pt(en)(N-AcMet-S,N), platinum chelate  with N-AcMet. 
 
b) [Pt(en)ox] reacted with N-Acetylmethionine (N-AcMet) at a 1:1 molar ratio  
 
Figure 11. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 1: 1, in D2O 4 hours. 
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Figure 12. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 1: 1, in D2O 24 hours. 
 
The reaction of [Pt(en)ox] with N-AcMet at mole ratio of 1:1 was monitored at 4 
hours and 24 hours (Figures 11, and 12). The signal at 2.5 ppm
33
 is a typical chemical 
shift for the S-CH3 resonance of a sulfur-coordinated N-AcMet. The N-AcMet connects 
to the Pt(en) via sulfur. The signal at 2.5 ppm, 2.7 ppm and 2.9 ppm is from the en ligand, 
which reacts with platinum and signal shift. These signals intensity is can indicate the 
complex of the product has C2 symmetry. That means two N-AcMet have reacted with 
platinum by the sulfur side. The small signals at 1.8 ppm and 1.7 ppm are from unreacted 
24 
 
 
 
N-AcMet and decrease over time.  The amount of the unreacted       N-AcMet decreases 
only slightly with time indicating the reaction between platinum and N-AcMet is quite 
complete in 4 hours.  
c) [Pt(en)ox] reacted with N-acetylmethionine (N-AcMet) at 1:2 molar ratio 
The reaction for [Pt(en)ox] with N-AcMet at a mole ratio of 1: 2 was monitored at 
4 hour and 24 hours (Figures 13. and 14). Signals at 2.5 ppm, 2.7 ppm and 2.9 ppm as 
compared to those at a 1:1 molar ratio did not change significantly, except that more 
intense signals from unreacted N-AcMet were observed. 
 
Figure 13. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 1: 2, in D2O 4 hours. 
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Figure 14. 
1
H NMR spectrum for Pt(en)ox: N-AcMet, molar ration 1: 2, in D2O 24 hours. 
 
In Figure 13 and Figure 14, the partial spectra from 2.0~3.0 ppm, indicates the 
product could be either mono or bis chelate complex
34
. From Figure 10, a molar 1:1 ratio 
with the signals between the 2.0~2.5 ppm shows that there is only one of S-CH3 signal 
shift. For Figures 12, and 14, the signals from the 2.5~3.0 ppm is muti-signal indicating 
two S-CH3 be coordinated together.    
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From the molar ratio 1:1 to 1:2, the [Pt(en)ox]  reacts with N-AcMet. The signals 
intensity at 2.5 ppm, 2.7 ppm and 2.9 ppm indicate the S-CH3 connect with platinum and 
have two N-Ac Met react with the platinum. The final product is symmetric predicted to 
be: 
 
Figure 15. Predicted structure of Pt(en)(N-AcMet-S)2 complex. 
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2. Reaction of [Pt(en)ox] with  Methionine (Met):  
a) [Pt(en)ox] reaction with Methionine (Met) at 2:1 molar ratio 
The reaction of [Pt(en)ox] with Met at a molar ratio of 2:1 was monitored at 4 
hours and 24 hours. In Figure 7, the signals at 2.3 ppm and 2.7 ppm are assigned to the H 
in S-CH3 and the en of the product. Two Mets react with [Pt(en)ox] and replace the 
oxalate to form a bis-Met product. The signal at 2.5 ppm is from unreacted en. The signal 
at 3.2 ppm is from free ethylenediamine, which means the en ligand on the Pt(en) 
compound was replaced by Met.  The platinum compound reacts with two methionine 
residues connecting on the nitrogen and sulfur atoms, and becomes [Pt(Met)2]. 
Comparing the intensity at 24 hours, the signals at 3.2 ppm and 2.3 ppm increase with 
time as the product [Pt(en)(Met)2] decrease and the free en ligand is displaced. The tiny 
signal at 1.9 ppm is unreacted Met, and the signal reduces with time.   
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Figure 16. 
1
H NMR spectrum for Pt(en)ox: N-Met, molar ration 2: 1, in D2O 4 hours. 
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Figure 17. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 2: 1, in D2O 24 hours. 
 
 
 
 
 
30 
 
 
 
The predicted structures for the methionine reacted with [Pt(en)ox] to form bis-
chelate, Pt(Met-S,N)2 complex and [Pt(en)(Met-S)2]
2+
 complex: 
 
Figure 18. Bis-chelate for Pt(Met-S,N)2 complex. 
 
Figure 19. [Pt(en)(Met-S)2]
2+
 complex. 
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b)  [Pt(en)ox] reaction with Methionine (Met) at 1:1 molar ratio 
  In Figure 20, 
1
H NMR spectroscopy was used to monitor the reaction of [Pt(en)ox] 
and Met at a molar ratio 1:1.  The signal at 2.4 ppm is assigned to the H of  the S-CH3 
from the product, which is [Pt(en)(Met-S)2]. The signal at 3.2 ppm is the free 
ethylenediamine and indicates the en ligand was replaced by Met. The signal at 2.0 ppm 
is the unreacted methionine. 
 
Figure 20. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 1: 1, in D2O 24 hours. 
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c) [Pt(en)ox] reaction with Methionine (Met) at 1:2 molar ratio 
The reaction of [Pt(en)ox] with Met at a molar ratio of 1:2 after 4 hours in D2O is 
shown in Figure 21. The signal at 2.4 ppm is from the H of S-CH3 of [Pt(en)(Met-S)2]. 
The unreacted Met has a signal at 2.0 ppm. As the reaction proceeds with time, the signal 
at 3.2 ppm increases from 4 hours to 24 hours; while more of the en ligand was replaced 
by the Met. The signal at 2.7 ppm was displaced for the 24 hr reaction, which means 
[Pt(Met-N,S)2], was the final product.  
 
Figure 21. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 1: 2, in D2O 4 hours. 
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Figure 22. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 1: 2, in D2O 24 hours. 
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d) [Pt(en)ox] reaction with Methionine (Met) at a 1:4  molar ratio 
The reaction of [Pt(en)ox] with Met at a molar ratio 1:4 is shown in Figures 23 
and 24. The signal at 2.4 ppm is the hydrogen of the Met of [Pt(en)(Met-S)2] bis-product. 
The unreacted Met is at 2.0 ppm. The reaction shows the [Pt(en)ox] reaction with Met, 
with products bis-chelate, [Pt(Met-N,S)2], and bis [Pt(en)(Met-S)2]. 
 
Figure 23. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 1: 4, in D2O 4 hours. 
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 Figure 24. 
1
H NMR spectrum for Pt(en)ox: Met, molar ration 1: 4, in D2O 24 hours. 
 The methoinine connects with platinum compound on the sulfur and nitrogen, that 
product becomes the bis complex. Figure 24, the signals around 2.5 ppm are from the 
product. But the signal at the 3.2 ppm is the free en ligand, which indicates the en was 
replaced, and platinum would bond with the methionine at nitrogen.    
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VI. DISCUSSION 
It was found that the [Pt(en)ox] complex reacts with methionine (Met) and residue 
N-acetylmethionine (N-AcMet) to form mono (Pt-S) adducts and bis (Pt-S-S) adducts. 
Typically, [Pt(en)ox] reacts with Met and the Met replaces the en ligand and makes 
[Pt(Met-S, N)2].  
Platinum connecting with sulfur is favored over connecting with oxygen and 
nitrogen. Because the platinum is of low electronegativity, and has low-energy lying 
LUMO, which could be the soft Lewis acid to accept electron. Comparing sulfur with 
nitrogen and oxygen, the sulfur has a large atomic radius, high polarizability, and low 
electronegativity, that sulfur could be soft base better than nitrogen and oxygen. 
Following HSAB theory, Lewis soft acids reacts faster and form stronger bonds with soft 
bases. Compared with sulfur, the affinity of the nitrogen and oxygen, a electron donor, is 
more suitable for a low polarizable and high electronegativity metal ion, which is strong 
Lewis acid
35
. Platinum connects with sulfur faster than with nitrogen and oxygen.  
In the reaction of the platinum compound reacting with methionine at a the molar 
ratio of 2:1, the en ligand was replaced and the new product is, [Pt(Met-S,N)2]. The new 
product has a six ring-membered chelate, compared to five membered ring for 
[Pt(en)(Met-S)2]. 
The cisplatin analog [Pt(en)(H2O)2]
2+
  (en=ethane-1,2-diamine) reacting with 
complex containing methionine (met) di- and tri- peptides would have N(amino), 
S(thiother) and N(amino) and N”(amide) chelation modes. The reaction at pH <8.7 have 
the N, S complexes, but the reaction at pH >7.4 has the N, N” complexes dominate for 
36 
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these bioligands
36
. On the reaction with one Met and one N-AcMet, the pH is around 
4.6~ 6.0 and the products are mono, and bis chealte products connecting via the sulfur 
and nitrogen. In the future, changing the solution pH value could make the platinum 
compound connect with amino acid on nitrogen or sulfur.  
The product of [Pt(en)ox] with excess methionine is Pt connected to two 
methionines via S and N; the en ligand is replaced. In the future, studies will focus on the 
product of reaction at different pH and time differences.  [Pt(en)ox] reacting with 
methionine should have a ring-opened intermediate.   
The reactions with N-AcMet and Met both form the bis-products, but for the 
reaction with Met the en ligand replaced. The N of the N-AcMet is sp
2
 hybridized, so the 
lone pair of nitrogen is, therefore, not available for coordination. 
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